Table 3.
Outcomes after 24 weeks of treatment with insulin aspart as part of a basal-bolus regimen
| Measurement | Age ≤40 years | Age >40–65 years | Age >65 years | |||
|---|---|---|---|---|---|---|
| Baseline | 24 weeks | Baseline | 24 weeks | Baseline | 24 weeks | |
| % patients with HbA1c <7.0%a | ||||||
| Entire cohort | 4.1 | 32.8 | 3.5 | 35.9 | 6.9 | 34.5 |
| n | 517 | 411 | 2,543 | 2,258 | 580 | 495 |
| Insulin-experienced | 5.3 | 32.2 | 3.7 | 35.7 | 7.7 | 32.0 |
| n | 322 | 270 | 1,551 | 1,386 | 364 | 322 |
| Insulin-naive | 2.1 | 34.0 | 3.2 | 36.1 | 5.6 | 39.3 |
| n | 195 | 141 | 992 | 872 | 216 | 173 |
| Measurement | Age ≤40 years | Age >40–65 years | Age >65 years | |||
|---|---|---|---|---|---|---|
| Baseline | Change after 24 weeks | Baseline | Change after 24 weeks | Baseline | Change after 24 weeks | |
| FPG before breakfast | ||||||
| Entire cohort, mmol/l | 11.3 (4.5) | −4.4*** (4.5) | 10.9 (3.6) | −3.9*** (3.7) | 10.7 (4.2) | −3.6*** (4.3) |
| Entire cohort, mg/dl | 203.2 (81.3) | −79.4*** (81.9) | 196.6 (65.4) | −71.0*** (66.2) | 192.4 (74.8) | −65.0*** (77.0) |
| n | 384 | 2,210 | 493 | |||
| Insulin-experienced, mmol/l | 10.4 (3.9) | −3.6*** (3.9) | 10.3 (3.3) | −3.3*** (3.4) | 10.3 (4.0) | −3.1*** (4.1) |
| Insulin-experienced, mg/dl | 187.9 (70.6) | −65.2*** (70.6) | 185.0 (60.1) | −59.8*** (60.8) | 186.2 (72.2) | −55.8*** (73.9) |
| n | 242 | 1,334 | 309 | |||
| Insulin-naive, mmol/l | 12.7 (5.1) | −5.8*** (5.2) | 11.9 (3.8) | −4.9*** (3.9) | 11.3 (4.3) | −4.5*** (4.4) |
| Insulin-naive, mg/dl | 229.3 (91.3) | −103.6*** (93.7) | 214.3 (69.1) | −88.0*** (70.2) | 202.9 (78.0) | −80.3*** (79.7) |
| n | 142 | 876 | 184 | |||
| PPG after breakfast | ||||||
| Entire cohort, mmol/l | 14.8 (5.0) | −5.9*** (4.9) | 14.4 (4.7) | −5.5*** (4.7) | 14.7 (5.1) | −5.6*** (5.3) |
| Entire cohort, mg/dl | 266.1 (89.7) | −106.6*** (87.5) | 260.2 (84.1) | −99.9*** (83.9) | 264.4 (92.5) | −101.6*** (95.3) |
| n | 303 | 1,660 | 371 | |||
| Insulin-experienced, mmol/l | 14.1 (4.7) | −5.2*** (4.5) | 13.6 (4.3) | −4.8*** (4.3) | 14.3 (5.1) | −5.2*** (5.2) |
| Insulin-experienced, mg/dl | 253.7 (83.8) | −92.8*** (80.9) | 245.2 (78.1) | −87.1*** (78.2) | 257.9 (92.2) | −93.5*** (94.5) |
| n | 199 | 999 | 232 | |||
| Insulin-naive, mmol/l | 16.1 (5.3) | −7.4*** (5.2) | 15.7 (4.9) | −6.6*** (4.9) | 15.3 (5.1) | −6.4*** (5.3) |
| Insulin-naive, mg/dl | 289.9 (95.9) | −132.9*** (93.8) | 282.9 (87.7) | −119.2*** (88.5) | 275.3 (92.4) | −115.2*** (95.5) |
| n | 104 | 661 | 139 | |||
| Body weight (kg) | ||||||
| Entire cohort | 72.0 (16.8) | 0.4 (3.8) | 79.8 (17.3) | −0.4*** (3.9) | 73.5 (14.7) | 0.1 (3.6) |
| n | 423 | 2,317 | 518 | |||
| Insulin-experienced | 71.8 (16.6) | 0.6** (3.6) | 82.3 (17.0) | −0.5*** (3.7) | 75.3 (14.3) | −0.1 (3.4) |
| n | 269 | 1,410 | 329 | |||
| Insulin-naive | 72.3 (17.0) | −0.1 (4.1) | 76.0 (17.1) | −0.2 (4.2) | 70.3 (15.1) | 0.5 (4.0) |
| n | 154 | 907 | 189 | |||
| HRQoL (UK VAS)b | ||||||
| Entire cohort | 0.799 (0.236) | 0.062*** (0.267) | 0.710 (0.239) | 0.116*** (0.242) | 0.657 (0.270) | 0.141*** (0.251) |
| n | 257 | 1,560 | 432 | |||
| Insulin-experienced | 0.753 (0.237) | 0.119*** (0.275) | 0.695 (0.232) | 0.115*** (0.239) | 0.640 (0.263) | 0.156*** (0.242) |
| n | 129 | 869 | 255 | |||
| Insulin-naive | 0.845 (0.226) | 0.005 (0.247) | 0.729 (0.246) | 0.116*** (0.245) | 0.681 (0.277) | 0.118*** (0.263) |
| n | 128 | 691 | 177 | |||
Due to the observational nature of the study, data were not collected or not recorded for some patients. All values are mean (SD)
FPG fasting plasma glucose; HbA 1c glycated hemoglobin; HRQoL health-related quality of life; PPG post-prandial plasma glucose; VAS visual analog scale
* p < 0.05 vs. baseline; ** p < 0.01 vs. baseline; *** p < 0.001 vs. baseline
aStatistical analysis was not performed on these data
bUK VAS score was calculated using data from EQ-5D scores (1.00 = full health; 0 = deceased)